Drug Manufacturers - Specialty & Generic · Healthcare
Board Member
2018-01-01–present
Board Member
Elanco Animal Health Inc (ELAN)Equibles does not estimate personal net worth.
Get an email with a short summary when Elanco Animal Health Inc publishes a filing, an earnings call transcript or a press release.
Get ELAN alertsLawrence Kurzius is recorded as Board Member at Elanco Animal Health Inc (ELAN) since May 30, 2024. The newest filing on record that lists Lawrence Kurzius as Board Member at Elanco Animal Health Inc (ELAN) is dated April 8, 2026. Earlier roles on record: Chairman at Mccormick & Co Inc (MKC) until December 31, 2024. Elanco Animal Health Inc reported in an 8-K filed June 4, 2024 that Lawrence Kurzius was appointed member of the Board, effective May 30, 2024. The proxy statement of Mccormick & Co Inc reports total compensation of $6,657,928 for Lawrence Kurzius in fiscal 2024, including a base salary of $1,298,077. Disclosed compensation is on record for 8 fiscal years. Lawrence Kurzius has spoken on 13 earnings calls across 1 company, most recently for Mccormick & Co Inc on June 29, 2023. Elanco Animal Health Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other companies whose calls Lawrence Kurzius spoke on are classified in the Consumer Defensive sector. Other leadership on record at Elanco Animal Health Inc includes Jeffrey N. Simmons (CEO and Board Member), Jeffrey Simmons (CEO and Board Member), Robert (Bob) VanHimbergen (CFO) and 7 others.
“the Board reappointed Ms. Turner to the Board as a member of the 2025 class and Mr. Kurzius to the Board as a member of the 2026 class, in all cases effective immediately upon completion of the Company’s annual meeting of shareholders on May 30, 2024 (the “2024 Annual Meeting”) and with Ms. Turner’s and Mr. Kurzius’ service on the Board deemed to have continued uninterrupted.”
“To start, last night, we announced that Brendan Foley will become McCormick’s next Chief Executive Officer on September 1, and he is joining the Board of Directors immediately.”
“We are pleased with the start of the year. We delivered solid first quarter results that reflect strong demand and early results from our actions to increase our profit realization in 2023.”
“Our fourth quarter concluded a challenging and volatile year that impacted our ability to deliver on our expectations and our financial performance.”
“Third quarter sales increased 3% from the year-ago period as anticipated.”
“I'd like to start by welcoming Brendan to this morning's call. In addition to his continuing role as President of our Global Consumer business, Brendan now has responsibility for our business worldwide in his newly appointed role as President and COO.”
2024-05-30–present
Last confirmed April 8, 2026
2018-01-01–2024-05-30
Start not stated–2024-12-31
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member
2018-01-01–present
Packaged Foods · Consumer Defensive
Chairman
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Mccormick & Co Inc (MKC) | Former Executive Chairman | $1,298,077 | $6,657,928 |
| 2023 | Mccormick & Co Inc (MKC) | Former Executive Chairman | $1,250,000 | $12,602,133 |
| 2022 | Mccormick & Co Inc (MKC) | Former Executive Chairman | $1,250,000 | $10,426,035 |
| 2021 | Mccormick & Co Inc (MKC) | Executive Chairman | $1,250,000 | $12,718,656 |
| 2020 | Mccormick & Co Inc (MKC) | Chairman and Chief Executive Officer | $1,250,000 | $19,546,334 |
| 2019 | Mccormick & Co Inc (MKC) | Chairman, President and Chief Executive Officer | $1,250,000 | $12,769,184 |
| 2018 | Mccormick & Co Inc (MKC) | Chairman, President and Chief Executive Officer | $1,163,462 | $14,836,426 |
| 2017 | Mccormick & Co Inc (MKC) | Chairman, President and Chief Executive Officer | $965,385 | $9,048,299 |